Design, synthesis and evaluation of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes

被引：0

作者：

Das, Saibal Kumar ^{[1
]}

Abbineni, Chandrasekhar ^{[1
]}

Rao, Krovvidi Venkata Lakshmi Narasimha ^{[1
]}

Iqbal, Javed ^{[1
]}

Babu, Ravi Krishna ^{[1
]}

Chakrabarti, Ranjan ^{[1
]}

机构：

[1] Dr Reddys Labs Ltd, Metab Disorders Grp, Discovery Res, Hyderabad 500049, Andhra Pradesh, India

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2007年 / 4卷 / 01期

关键词：

PPAR; diabetes; synthesis; ethyl 3-(4-aminophenyl)-2-ethoxypropionate; dyslipidemia and plasma glucose;

D O I：

暂无

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The design, synthesis and evaluation of several dual PPAR alpha/gamma agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes and associated dyslipidemia are described. Among them, compound 5cb was found to possess a potent dual PPAR alpha/gamma agonist property. It significantly reversed diabetic hyperglycemia while improving overall lipid homeostasis in preclinical animal models.

引用

页码：27 / 32

页数：6

共 50 条

[21] Eigenvalue analysis of peroxisome proliferator-activated receptor γ agonists
Liao, CZ
Xie, AH
Shi, LM
Zhou, JJ
Lu, XP
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (01): : 230 - 238
[22] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Kolatkar, Nikheel S.
AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E11 - E11
[23] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ AGONISTS AS NEUROPROTECTIVE AGENTS
Kaundal, Ravinder K.
Sharma, Shyam S.
DRUG NEWS & PERSPECTIVES, 2010, 23 (04) : 241 - 256
[24] Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B
Fruchart, JC
DIABETES, 2005, 54 (08) : 2460 - 2470
[25] Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
Grommes, C
Landreth, GE
Heneka, MT
LANCET ONCOLOGY, 2004, 5 (07): : 419 - 429
[26] Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor α agonists
Faucher, Nicolas
Martres, Paul
Laroze, Alain
Pineau, Olivier
Potvain, Florent
Grillot, Didier
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (02) : 710 - 715
[27] Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H
Khoudoli, GA
Graham, TL
Palmer, CNA
PHARMACOLOGY & THERAPEUTICS, 2002, 95 (01) : 47 - 62
[28] Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists
Fracchiolla, Giuseppe
Laghezza, Antonio
Piemontese, Luca
Parente, Mariagiovanna
Lavecchia, Antonio
Pochetti, Giorgio
Montanari, Roberta
Di Giovanni, Carmen
Carbonara, Giuseppe
Tortorella, Paolo
Novellino, Ettore
Loiodice, Fulvio
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (06) : 2141 - 2151
[29] Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
Fievet, Catherine
Staels, Bart
CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11 (04) : 281 - 288
[30] Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
Catherine Fiévet
Bart Staels
Current Atherosclerosis Reports, 2009, 11 : 281 - 288

← 1 2 3 4 5 →